Mechanistic Study of Potent Fluorinated EGFR Kinase Inhibitors with a Quinazoline Scaffold against L858R/T790M/C797S Resistance Mutation: Unveiling the Fluorine Substituent Cooperativity Effect on the Inhibitory Activity

2020 ◽  
Vol 124 (28) ◽  
pp. 5813-5824
Author(s):  
Farideh Badichi Akher ◽  
Abdolkarim Farrokhzadeh ◽  
Neil Ravenscroft ◽  
Michelle M. Kuttel
ChemInform ◽  
2004 ◽  
Vol 35 (30) ◽  
Author(s):  
Allan Wissner ◽  
Philip R. Hamann ◽  
Ramaswamy Nilakantan ◽  
Lee M. Greenberger ◽  
Fei Ye ◽  
...  

2013 ◽  
Vol 34 (9) ◽  
pp. 2680-2684
Author(s):  
Hyejin Park ◽  
Kyeung Kyu Kim ◽  
ChangHoon Kim ◽  
Jae-Min Shin ◽  
Kyoung Tai No

2018 ◽  
Vol 54 (54) ◽  
pp. 7479-7482 ◽  
Author(s):  
Mu Yang ◽  
Hanzhi Wu ◽  
Julie Chu ◽  
Lucas A. Gabriel ◽  
Y. Kim ◽  
...  

Platinum-modified tyrosine kinase inhibitors show strong and selective EGFR kinase binding and form adducts with a pharmacologically relevant cysteine residue.


2019 ◽  
Vol 10 (6) ◽  
pp. 869-873 ◽  
Author(s):  
Qiannan Li ◽  
Tao Zhang ◽  
Shiliang Li ◽  
Linjiang Tong ◽  
Junyu Li ◽  
...  

Diagnostics ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. 527
Author(s):  
Amandine Billaud ◽  
Veronique Verriele ◽  
Jonathan Dauvé ◽  
Louise-Marie Chevalier ◽  
Alain Morel

Targeted therapies and, more precisely, EGFR tyrosine kinase inhibitors (TKIs) have been a major improvement in the therapeutic management of EGFR-mutated non-small-cell lung cancers (NSCLCs). Earlier administration of these TKIs throughout tumor progression is imperative to improve patient outcomes. Consequently, studies have focused on refining the characterization of biomarkers, especially concerning the resistance mutation p.Thr790Met of EGFR. Herein, we developed peptide nucleic acid (PNA)-mediated PCR clamping followed by pyrosequencing, favoring enrichment of the mutated fraction. A preamplification step was first added to increase the amplifiable DNA fraction. Throughout the application of our method on DNA extracted from FFPE samples of 46 patients with NSCLC who had relapsed under first-generation EGFR TKI, we evaluated a sensitivity of 93.3% and a specificity of 100%. All 19 patients who were positive for the p.Thr790Met mutation with NGS were also found to be positive with our protocol. The only discordant case was a sample with no mutation detected with NGS, but which was positive with PNA. This protocol allows for the detection of the p.Thr790Met mutation with a sensitivity of 0.5% which will permit earlier detection and an improvement of therapeutic management.


Sign in / Sign up

Export Citation Format

Share Document